BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83:1306-1310. [PMID: 22208977 DOI: 10.1016/j.ijrobp.2011.09.049] [Cited by in Crossref: 338] [Cited by in F6Publishing: 331] [Article Influence: 28.2] [Reference Citation Analysis]
Number Citing Articles
1 Hathout L, Fields EC, Erickson BA. Stereotactic Body Radiation Therapy for Nodal Metastases in Gynecologic Cancers: Is it the Swan Song or the Opening Number? Int J Radiat Oncol Biol Phys 2023;115:297-301. [PMID: 36621232 DOI: 10.1016/j.ijrobp.2022.07.1836] [Reference Citation Analysis]
2 Kita N, Tomita N, Takaoka T, Sudo S, Tsuzuki Y, Okazaki D, Niwa M, Torii A, Takano S, Niimi A, Hiwatashi A. Comparison of Recurrence Patterns between Adenocarcinoma and Squamous Cell Carcinoma after Stereotactic Body Radiotherapy for Early-Stage Lung Cancer. Cancers 2023;15:887. [DOI: 10.3390/cancers15030887] [Reference Citation Analysis]
3 Carlson PM, Patel RB, Birstler J, Rodriquez M, Sun C, Erbe AK, Bates AM, Marsh I, Grudzinski J, Hernandez R, Pieper AA, Feils AS, Rakhmilevich AL, Weichert JP, Bednarz BP, Sondel PM, Morris ZS. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination. J Immunother Cancer 2023;11. [PMID: 36639155 DOI: 10.1136/jitc-2022-005463] [Reference Citation Analysis]
4 Kucuk A, Topkan E, Durankus NK, Senyurek S, Akdemir EY, Sezen D, Bolukbasi Y, Selek U, Pehlivan B. Combined Stereotactic Radiosurgery and Immune Checkpoint Inhibitors for the Treatment of Brain Metastasis. Advancements in Cancer Research 2023. [DOI: 10.36255/treatment-brain-metastasis] [Reference Citation Analysis]
5 Farhat S, Rezaei N. Tumor Hyperprogression and Pseudoprogression After Immunotherapy. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_342-1] [Reference Citation Analysis]
6 Hintelmann K, Petersen C, Borgmann K. Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. Cancers (Basel) 2022;15. [PMID: 36612206 DOI: 10.3390/cancers15010211] [Reference Citation Analysis]
7 Li J, Lu W, Yang Y, Xiang R, Ling Y, Yu C, Zhou Y. Hybrid Nanomaterials for Cancer Immunotherapy. Adv Sci (Weinh) 2022;:e2204932. [PMID: 36567305 DOI: 10.1002/advs.202204932] [Reference Citation Analysis]
8 Hsu S, Chao Y, Hu Y, Zhang Y, Hong W, Chen Y, Chen R, Zeng Z, Du S. Radiotherapy Enhances Efficacy of PD-1 inhibitors in Advanced Liver Cancer: A Real-world Data.. [DOI: 10.21203/rs.3.rs-2317178/v1] [Reference Citation Analysis]
9 Götze TO, Prause M, Al-batran S. Adjuvante Studie PEARLDIFER. Forum 2022. [DOI: 10.1007/s12312-022-01160-x] [Reference Citation Analysis]
10 Liu L, Yuan M, Ding Z, Feng H, Zhang X, Liang N, Wang W, Wang J, Zhang Y, Zhou S, Kim AW, Castiglioni S, Suwinski R, Wang H, Hu P, Zhang J. Immunotherapy with radiotherapy fails to improve prognosis of patients with stage IV non-small cell lung cancer: a retrospective cohort analysis of the THUNDER-2 study. Transl Lung Cancer Res 2022;11:2507-20. [PMID: 36636420 DOI: 10.21037/tlcr-22-843] [Reference Citation Analysis]
11 Huan T, Li H, Tang B. Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1033512] [Reference Citation Analysis]
12 Kodintseva EА, Akleуev AA. Effect of chronic exposure on the concentration of NF-kB in peripheral blood lymphocytes. Ekologiya cheloveka (Human Ecology) 2022. [DOI: 10.17816/humeco108084] [Reference Citation Analysis]
13 Xiao Y, Zhuang H. Effect of stereotactic radiotherapy on immune microenvironment of lung cancer. Front Immunol 2022;13:1025872. [DOI: 10.3389/fimmu.2022.1025872] [Reference Citation Analysis]
14 Miljanic M, Montalvo S, Aliru M, Song T, Leon-Camarena M, Innella K, Vujovic D, Komaki R, Iyengar P. The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field. Cancers (Basel) 2022;14:4530. [PMID: 36139689 DOI: 10.3390/cancers14184530] [Reference Citation Analysis]
15 Woessner R, Borodovsky A, Sachsenmeier K, Scheuplein F, Wilkinson RW, Ye C, Dovedi S. Transplantable Syngeneic Murine Tumor Models. Animal Models for the Development of Cancer Immunotherapy 2022. [DOI: 10.1002/9781119535331.ch1] [Reference Citation Analysis]
16 Matsui JK, Perlow HK, Raj RK, Nalin AP, Lehrer EJ, Kotecha R, Trifiletti DM, Mcclelland S, Kendra K, Williams N, Owen DH, Presley CJ, Thomas EM, Beyer SJ, Blakaj DM, Ahluwalia MS, Raval RR, Palmer JD. Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. Biomedicines 2022;10:2211. [DOI: 10.3390/biomedicines10092211] [Reference Citation Analysis]
17 Remic T, Sersa G, Levpuscek K, Lampreht Tratar U, Ursic Valentinuzzi K, Cör A, Kamensek U. Tumor cell-based vaccine contributes to local tumor irradiation by eliciting a tumor model-dependent systemic immune response. Front Immunol 2022;13:974912. [DOI: 10.3389/fimmu.2022.974912] [Reference Citation Analysis]
18 Marco F, Gianluca A, Mariagrazia T, Luca EP. Overcoming immune-resistance in laryngeal cancer: a case report of the abscopal effect and nivolumab beyond progression. Immunotherapy 2022. [PMID: 36040238 DOI: 10.2217/imt-2021-0309] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Shi M, Chen Y, Ji D. The implications from the interplay of neoadjuvant chemoradiotherapy and the immune microenvironment in rectal cancer. Future Oncol 2022. [PMID: 36017694 DOI: 10.2217/fon-2022-0061] [Reference Citation Analysis]
20 Schaue D, Micewicz ED, Ratikan JA, Iwamoto KS, Vlashi E, Mcdonald JT, Mcbride WH. NRF2 Mediates Cellular Resistance to Transformation, Radiation, and Inflammation in Mice. Antioxidants 2022;11:1649. [DOI: 10.3390/antiox11091649] [Reference Citation Analysis]
21 Zhou X, Wang X. Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma. Biomedicines 2022;10:1990. [DOI: 10.3390/biomedicines10081990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Faroni L, Collie L, Gabrielli F, Baldotto C, Moraes F. Role of Stereotactic Radiation Therapy in Operable and Inoperable Early-Stage Non-small Cell Lung Cancer. Curr Treat Options Oncol 2022. [PMID: 35969313 DOI: 10.1007/s11864-022-01002-x] [Reference Citation Analysis]
23 Zhao Z, Bian J, Zhang J, Zhang T, Lu X. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. Front Oncol 2022;12:843707. [DOI: 10.3389/fonc.2022.843707] [Reference Citation Analysis]
24 Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258. [PMID: 35906199 DOI: 10.1038/s41392-022-01102-y] [Reference Citation Analysis]
25 Zhao C, Deng H, Chen X. Harnessing immune response using reactive oxygen Species-Generating/Eliminating inorganic biomaterials for disease treatment. Adv Drug Deliv Rev 2022;188:114456. [PMID: 35843505 DOI: 10.1016/j.addr.2022.114456] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kozin SV. Vascular damage in tumors: a key player in stereotactic radiation therapy? Trends Cancer 2022:S2405-8033(22)00130-3. [PMID: 35835699 DOI: 10.1016/j.trecan.2022.06.002] [Reference Citation Analysis]
27 Lin J, Guo Q, Guo Z, Lu T, Chen G, Lin S, Chen M, Chen C, Lu J, Zong J, Tang L, Chen Y, Pan J. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma. Radiat Oncol 2022;17:117. [PMID: 35790987 DOI: 10.1186/s13014-022-02073-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Garde-Noguera J, Martín-Martín M, Obeso A, López-Mata M, Crespo IR, Pelari-Mici L, Juan Vidal O, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Current treatment landscape for oligometastatic non-small cell lung cancer. World J Clin Oncol 2022; 13(6): 485-495 [DOI: 10.5306/wjco.v13.i6.485] [Reference Citation Analysis]
29 Zhai ML, Zhang FY, Yang JR, Zhang S, Zhao L, Lin ZY, Wang J, Yu DD, Zhang T. Current status of neoadjuvant therapy for locally advanced rectal cancer in Wuhan Union Hospital Cancer Center. Radiat Oncol 2022;17:109. [PMID: 35718789 DOI: 10.1186/s13014-022-02081-8] [Reference Citation Analysis]
30 Chen PT, Hsieh CC, Chen MF. Role of vitamin D3 in tumor aggressiveness and radiation response for hepatocellular carcinoma. Mol Carcinog 2022. [PMID: 35611989 DOI: 10.1002/mc.23421] [Reference Citation Analysis]
31 Nenclares P, Rullan A, Tam K, Dunn LA, St John M, Harrington KJ. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations. Am Soc Clin Oncol Educ Book 2022;42:1-16. [PMID: 35522916 DOI: 10.1200/EDBK_351336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Mudassar F, Shen H, Cook KM, Hau E. Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. J Med Imag Rad Onc. [DOI: 10.1111/1754-9485.13416] [Reference Citation Analysis]
33 Charpentier M, Spada S, Vannest S, Demaria S. Radiation therapy-induced remodeling of the tumor immune microenvironment. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 David S, Tan J, Siva S, Karroum L, Savas P, Loi S. Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. Biomedicines 2022;10:821. [DOI: 10.3390/biomedicines10040821] [Reference Citation Analysis]
35 Kotecha R, Tonse R, Menendez MAR, Williams A, Diaz Z, Tom MC, Hall MD, Mehta MP, Alvarez R, Siomin V, Odia Y, Ahluwalia MS, McDermott MW. Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. Sci Rep 2022;12:4567. [PMID: 35296750 DOI: 10.1038/s41598-022-08507-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Wang Z, Qiang Y, Shen Q, Zhu X, Song Y. Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series. Front Oncol 2022;12:779251. [DOI: 10.3389/fonc.2022.779251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Exner SA, Behrens F, Fehlauer F. Abskopale Reaktion – ein unterschätzter Effekt mit großem Potenzial. Deutsche Zeitschrift für Onkologie 2022;54:9-13. [DOI: 10.1055/a-1731-6050] [Reference Citation Analysis]
38 Deshpande A, Rule W, Rosenthal A. Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas. Curr Treat Options Oncol 2022;23:89-98. [PMID: 35167008 DOI: 10.1007/s11864-021-00935-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Swamy K. Stereotactic Body Radiotherapy Immunological Planning-A Review With a Proposed Theoretical Model. Front Oncol 2022;12:729250. [PMID: 35155221 DOI: 10.3389/fonc.2022.729250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, Thel H, Hoyos D, Mehta A, Arshad S, Lieb DJ, Drapek LC, Blaszkowsky LS, Giantonio BJ, Weekes CD, Zhu AX, Goyal L, Nipp RD, Dubois JS, Van Seventer EE, Foreman BE, Matlack LE, Ly L, Meurer JA, Hacohen N, Ryan DP, Yeap BY, Corcoran RB, Greenbaum BD, Ting DT, Hong TS. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer 2021;2:1124-35. [PMID: 35122060 DOI: 10.1038/s43018-021-00269-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
41 Tjong M, Louie A, Singh A, Videtic G, Stephans K, Plumridge N, Harden S, Slotman B, Alongi F, Guckenberger M, Siva S. Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung – The Knockout Punch. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
42 Bozorgmehr F, Eichhorn F, Tufman A, Rieken S, Thomas M. Thorakale Onkologie – frühe Stadien. Onkologe 2022;28:50-54. [DOI: 10.1007/s00761-021-01092-6] [Reference Citation Analysis]
43 Helm A, Fournier C, Durante M. Particle radiotherapy and molecular therapies: mechanisms and strategies towards clinical applications. Expert Rev Mol Med 2022;24:e8. [PMID: 35101155 DOI: 10.1017/erm.2022.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Zhao X, Li J, Zheng L, Yang Q, Chen X, Chen X, Yu Y, Li F, Cui J, Sun J. Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non–Small-Cell Lung Cancer. Front Mol Biosci 2022;9:786864. [DOI: 10.3389/fmolb.2022.786864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Badrigilan S, Meola A, Chang SD, Rezaeian S, Nemati H, Almasi T, Rostampour N. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study. Br J Neurosurg 2022;:1-11. [PMID: 34979828 DOI: 10.1080/02688697.2021.2022098] [Reference Citation Analysis]
46 Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer 2022;3:1300-17. [PMID: 36434392 DOI: 10.1038/s43018-022-00450-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Carlson PM, Morris ZS. Translational Development and Testing of Theranostics in Combination with Immunotherapies. Nuclear Medicine and Immunology 2022. [DOI: 10.1007/978-3-030-81261-4_12] [Reference Citation Analysis]
48 Miyasaka Y, Sato H, Okano N, Kubo N, Kawamura H, Ohno T. A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy. Cancers (Basel) 2021;14:203. [PMID: 35008367 DOI: 10.3390/cancers14010203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Bazyar S, O'Brien ET 3rd, Benefield T, Roberts VR, Kumar RJ, Gupta GP, Zhou O, Lee YZ. Immune-Mediated Effects of Microplanar Radiotherapy with a Small Animal Irradiator. Cancers (Basel) 2021;14:155. [PMID: 35008319 DOI: 10.3390/cancers14010155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Wen L, Tong F, Zhang R, Chen L, Huang Y, Dong X. The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy. Front Oncol 2021;11:799957. [PMID: 34956911 DOI: 10.3389/fonc.2021.799957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Yao Y, Qi Z, Zhu Q, Zhao Q, Zhang Z, Fu S, Zhou L, Zhu J, Liu Z, Xu H, Huang Y, Xue J, Qin S. Erb‐(IL10) 2 induces abscopal antitumor effects of radiotherapy through the activation and recruitment of lymph node CD8 + T cells. Precision Radiation Oncology 2021;5:226-36. [DOI: 10.1002/pro6.1138] [Reference Citation Analysis]
52 Loo M, Clavier JB, Attal Khalifa J, Moyal E, Khalifa J. Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review. Cancers (Basel) 2021;13:6086. [PMID: 34885193 DOI: 10.3390/cancers13236086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 De Felice M, Tammaro M, Leopardo D, Ianniello GP, Turitto G. Moving towards the Future of Radio-Immunotherapy: Could We “Tailor” the Abscopal Effect on Head and Neck Cancer Patients? Immuno 2021;1:410-23. [DOI: 10.3390/immuno1040029] [Reference Citation Analysis]
54 Zhou H, Yang P, Li H, Zhang L, Li J, Zhang T, Sheng C, Wang J. Carbon ion radiotherapy boosts anti-tumour immune responses by inhibiting myeloid-derived suppressor cells in melanoma-bearing mice. Cell Death Discov 2021;7:332. [PMID: 34732697 DOI: 10.1038/s41420-021-00731-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Boustani J, Lecoester B, Baude J, Latour C, Adotevi O, Mirjolet C, Truc G. Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies. Cancers (Basel) 2021;13:4893. [PMID: 34638376 DOI: 10.3390/cancers13194893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Ni J, Zhou Y, Wu L, Ai X, Dong X, Chu Q, Han C, Wang X, Zhu Z. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiat Oncol 2021;16:177. [PMID: 34526044 DOI: 10.1186/s13014-021-01905-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
57 Fleischmann M, Glatzer M, Rödel C, Tselis N. Radioimmunotherapy: future prospects from the perspective of brachytherapy. J Contemp Brachytherapy 2021;13:458-67. [PMID: 34484362 DOI: 10.5114/jcb.2021.108601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Eke I, Aryankalayil MJ, Bylicky MA, Sandfort V, Vanpouille-Box C, Nandagopal S, Graves EE, Giaccia AJ, Coleman CN. Long-term expression changes of immune-related genes in prostate cancer after radiotherapy. Cancer Immunol Immunother 2021. [PMID: 34435232 DOI: 10.1007/s00262-021-03036-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Belluomini L, Dionisi V, Palmerio S, Vincenzi S, Avancini A, Casali M, Riva ST, Menis J, Mazzarotto R, Pilotto S, Milella M. Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction. Clin Lung Cancer 2021:S1525-7304(21)00185-6. [PMID: 34470722 DOI: 10.1016/j.cllc.2021.07.004] [Reference Citation Analysis]
60 Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol 2021;7:1051-9. [PMID: 33885725 DOI: 10.1001/jamaoncol.2021.0168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
61 Boerma M, Davis CM, Jackson IL, Schaue D, Williams JP. All for one, though not one for all: team players in normal tissue radiobiology. Int J Radiat Biol 2021;:1-21. [PMID: 34129427 DOI: 10.1080/09553002.2021.1941383] [Reference Citation Analysis]
62 Hui C, Chau B, Gan G, Stokes W, Karam SD, Amini A. Overcoming Resistance to Immunotherapy in Head and Neck Cancer Using Radiation: A Review. Front Oncol 2021;11:592319. [PMID: 34277390 DOI: 10.3389/fonc.2021.592319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Lai JZ, Zhu YY, Liu Y, Zhou LL, Hu L, Chen L, Zhang QY. Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity. Front Oncol 2021;11:690188. [PMID: 34249740 DOI: 10.3389/fonc.2021.690188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
64 Green M, Van Nest SJ, Soisson E, Huber K, Liao Y, McBride W, Dominello MM, Burmeister J, Joiner MC. Three discipline collaborative radiation therapy (3DCRT) special debate: We should treat all cancer patients with hypofractionation. J Appl Clin Med Phys 2020;21:7-14. [PMID: 32602186 DOI: 10.1002/acm2.12954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR; trial investigators. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol 2021;22:1023-33. [PMID: 34126044 DOI: 10.1016/S1470-2045(21)00196-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 47] [Article Influence: 31.0] [Reference Citation Analysis]
66 Strange CD, Shroff GS, Truong MT, Nguyen QN, Vlahos I, Erasmus JJ. Imaging of the post-radiation chest in lung cancer. Clin Radiol 2021:S0009-9260(21)00253-1. [PMID: 34090709 DOI: 10.1016/j.crad.2021.04.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 van Schaik TA, Chen KS, Shah K. Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy? Front Oncol 2021;11:678562. [PMID: 34141622 DOI: 10.3389/fonc.2021.678562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Akanda ZZ, Neeson PJ, John T, Barnett S, Hanna GG, Miller A, Jennens R, Siva S. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2766-78. [PMID: 34295676 DOI: 10.21037/tlcr-20-1117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Scoccianti S, Olmetto E, Pinzi V, Osti MF, Di Franco R, Caini S, Anselmo P, Matteucci P, Franceschini D, Mantovani C, Beltramo G, Pasqualetti F, Bruni A, Tini P, Giudice E, Ciammella P, Merlotti A, Pedretti S, Trignani M, Krengli M, Giaj-Levra N, Desideri I, Pecchioli G, Muto P, Maranzano E, Fariselli L, Navarria P, Ricardi U, Scotti V, Livi L. Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro Oncol 2021:noab129. [PMID: 34050669 DOI: 10.1093/neuonc/noab129] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
70 Swamy K. Vascular-immuno-phenotypic (VIP) model for locally advanced and oligo-metastatic cancer: A hypothesis. Med Hypotheses 2021;152:110618. [PMID: 34102599 DOI: 10.1016/j.mehy.2021.110618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Sia J, Hagekyriakou J, Chindris I, Albarakati H, Leong T, Schlenker R, Keam SP, Williams SG, Neeson PJ, Johnstone RW, Haynes NM. Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. Int J Radiat Oncol Biol Phys 2021;111:502-14. [PMID: 34023423 DOI: 10.1016/j.ijrobp.2021.05.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
72 Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neuro Oncol 2021;23:677-86. [PMID: 33173935 DOI: 10.1093/neuonc/noaa260] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
73 Anand S, Chan TA, Hasan T, Maytin EV. Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). Pharmaceuticals (Basel) 2021;14:447. [PMID: 34068491 DOI: 10.3390/ph14050447] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
74 Ukleja J, Kusaka E, Miyamoto DT. Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. Front Oncol 2021;11:663852. [PMID: 34041029 DOI: 10.3389/fonc.2021.663852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
75 Lippert TP, Greenberg RA. The abscopal effect: a sense of DNA damage is in the air. J Clin Invest 2021;131:148274. [PMID: 33938453 DOI: 10.1172/JCI148274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
76 Vito A, Rathmann S, Mercanti N, El-Sayes N, Mossman K, Valliant J. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. Int J Mol Sci 2021;22:4843. [PMID: 34063642 DOI: 10.3390/ijms22094843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Marciscano AE, Haimovitz-friedman A, Lee P, Tran PT, Tomé WA, Guha C, (Spring) Kong F, Sahgal A, El Naqa I, Rimner A, Marks LB, Formenti SC, Deweese TL. Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. International Journal of Radiation Oncology*Biology*Physics 2021;110:35-52. [DOI: 10.1016/j.ijrobp.2019.02.046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 16.5] [Reference Citation Analysis]
78 Yoon K, Chen YJ, Chao J. A narrative review of combining radiation and immunotherapy in gastroesophageal cancers. Transl Cancer Res 2021;10:2586-95. [PMID: 35116572 DOI: 10.21037/tcr-20-2210] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Reijmen E, De Mey S, De Mey W, Gevaert T, De Ridder K, Locy H, Martens S, De Blay E, Bouwens L, Debie P, Breckpot K, De Grève J, De Ridder M, Goyvaerts C. Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors. Int J Radiat Oncol Biol Phys 2021;111:272-83. [PMID: 33865948 DOI: 10.1016/j.ijrobp.2021.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
80 Azoulay M, Chang SD, Gibbs IC, Hancock SL, Pollom EL, Harsh GR, Adler JR, Harraher C, Li G, Hayden Gephart M, Nagpal S, Thomas RP, Recht LD, Jacobs LR, Modlin LA, Wynne J, Seiger K, Fujimoto D, Usoz M, von Eyben R, Choi CYH, Soltys SG. A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. Neuro Oncol 2020;22:1182-9. [PMID: 32002547 DOI: 10.1093/neuonc/noaa019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
81 Formenti SC, Demaria S. Future of Radiation and Immunotherapy. Int J Radiat Oncol Biol Phys 2020;108:3-5. [PMID: 32819614 DOI: 10.1016/j.ijrobp.2020.04.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
82 Kong Y, Ma Y, Zhao X, Pan J, Xu Z, Zhang L. Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers. Front Oncol 2021;11:638873. [PMID: 33859942 DOI: 10.3389/fonc.2021.638873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
83 Zhang N, Gao Y, Zeng Z, Luo Y, Jiang X, Zhang J, Li J, Zhang J, Gong Y, Xie C. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer. Clin Transl Oncol 2021;23:1827-37. [PMID: 33774805 DOI: 10.1007/s12094-021-02591-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
84 Fang PQ, Gunther JR, Wu SY, Dabaja BS, Nastoupil LJ, Ahmed S, Neelapu SS, Pinnix CC. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol 2021;11:648655. [PMID: 33842363 DOI: 10.3389/fonc.2021.648655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
85 Marcus D, Lieverse RIY, Klein C, Abdollahi A, Lambin P, Dubois LJ, Yaromina A. Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers (Basel) 2021;13:1468. [PMID: 33806808 DOI: 10.3390/cancers13061468] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
86 Liu C, Piao J, Shang Z. Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature. BMC Urol 2021;21:42. [PMID: 33743675 DOI: 10.1186/s12894-021-00813-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
87 Walker JM, Rolig AS, Charych DH, Hoch U, Kasiewicz MJ, Rose DC, McNamara MJ, Hilgart-Martiszus IF, Redmond WL. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer. J Immunother Cancer 2020;8:e000464. [PMID: 32457127 DOI: 10.1136/jitc-2019-000464] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
88 Lee BM, Seong J. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(10): 919-927 [PMID: 33776363 DOI: 10.3748/wjg.v27.i10.919] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
89 Desai R, Coxon AT, Dunn GP. Therapeutic applications of the cancer immunoediting hypothesis. Semin Cancer Biol 2021:S1044-579X(21)00052-3. [PMID: 33711414 DOI: 10.1016/j.semcancer.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
90 Huang J, Yang B, Peng Y, Huang J, Wong SHD, Bian L, Zhu K, Shuai X, Han S. Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy. Adv Funct Mater 2021;31:2011171. [DOI: 10.1002/adfm.202011171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
91 Yonezawa N, Murakami H, Demura S, Kato S, Miwa S, Yoshioka K, Shinmura K, Yokogawa N, Shimizu T, Oku N, Kitagawa R, Handa M, Annen R, Kurokawa Y, Fushimi K, Mizukoshi E, Tsuchiya H. Abscopal Effect of Frozen Autograft Reconstruction Combined with an Immune Checkpoint Inhibitor Analyzed Using a Metastatic Bone Tumor Model. Int J Mol Sci 2021;22:1973. [PMID: 33671258 DOI: 10.3390/ijms22041973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Rückert M, Deloch L, Frey B, Schlücker E, Fietkau R, Gaipl US. Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment. Cancers (Basel) 2021;13:714. [PMID: 33572437 DOI: 10.3390/cancers13040714] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
93 Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA. Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments. Cancers (Basel) 2021;13:678. [PMID: 33567530 DOI: 10.3390/cancers13040678] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
94 Li D, Zhu W, Zhou J, Peng M, Geng Q, Pu X, Wang M, Jiang H. Hypofractionated Low-Dose Radiotherapy Combined with Immune Checkpoint Inhibition in Metastatic Solid Tumors. Onco Targets Ther 2021;14:773-83. [PMID: 33568917 DOI: 10.2147/OTT.S289937] [Reference Citation Analysis]
95 Koukourakis IM, Giakzidis AG, Kouroupi M, Giatromanolaki A, Abatzoglou I, Karpouzis A, Koukourakis MI. Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. BJR Case Rep 2021;7:20200170. [PMID: 34131497 DOI: 10.1259/bjrcr.20200170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Wang Y. Advances in Hypofractionated Irradiation-Induced Immunosuppression of Tumor Microenvironment. Front Immunol 2020;11:612072. [PMID: 33569059 DOI: 10.3389/fimmu.2020.612072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
97 Modi C, Berim L, Isserow L, Malhotra J, Patel M, Langenfeld J, Aisner J, Almeldin D, Jabbour SK. Combining radiation therapy and immunotherapy for lung cancers: a narrative review. Shanghai Chest 2021;5:10. [PMID: 33521559 DOI: 10.21037/shc-20-66] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Peng J, Lalani AK, Swaminath A. Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors in metastatic renal cell carcinoma. Can Urol Assoc J 2021;15:281-6. [PMID: 33410742 DOI: 10.5489/cuaj.6963] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 de Almeida DVP, Fong L, Rettig MB, Autio KA. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough? Am Soc Clin Oncol Educ Book 2020;40:1-18. [PMID: 32343604 DOI: 10.1200/EDBK_278853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
100 Campbell AM, Decker RH. Immunotherapy and Radiotherapy: New Strategies. Lung Cancer 2021. [DOI: 10.1007/978-3-030-74028-3_10] [Reference Citation Analysis]
101 Abousaida B, Hsieh C, Venkatesulu BP, Krishnan S. Technological Advances in Radiotherapy. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_6] [Reference Citation Analysis]
102 Alcibar OL, Nadal E, Romero Palomar I, Navarro-Martin A. Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer. Transl Lung Cancer Res 2021;10:529-38. [PMID: 33569334 DOI: 10.21037/tlcr-2020-nsclc-04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
103 Saghazadeh A, Keshavarz-fathi M, Delavari F, Rezaei N. Radiation and Immunity: Hand in Hand from Tumorigenesis to Therapeutic Targets. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_30] [Reference Citation Analysis]
104 Shakfa N, Siemens DR, Koti M. Revisiting immunogenic cell death to improve treatment response in cancer. Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance 2021. [DOI: 10.1016/b978-0-12-821310-0.00008-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Zarnani A, Jafari D, Bozorgmehr M, Shabani M, Barzegar-yarmohammadi L, Ghaemimanesh F, Jeddi-tehrani M. Monoclonal Antibodies for Cancer Immunotherapy. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_15] [Reference Citation Analysis]
106 Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 2021;24:697-717. [PMID: 33820953 DOI: 10.1038/s41391-021-00340-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 22.0] [Reference Citation Analysis]
107 Cao K, Abbassi L, Romano E, Kirova Y. Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. Expert Rev Anticancer Ther 2021;21:501-10. [PMID: 33355024 DOI: 10.1080/14737140.2021.1868993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
108 Tubin S, Gupta S, Grusch M, Popper HH, Brcic L, Ashdown ML, Khleif SN, Peter-Vörösmarty B, Hyden M, Negrini S, Fossati P, Hug E. Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY). Cancers (Basel) 2020;13:E50. [PMID: 33375357 DOI: 10.3390/cancers13010050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
109 Chen M, Singh AK, Repasky EA. Highlighting the Potential for Chronic Stress to Minimize Therapeutic Responses to Radiotherapy through Increased Immunosuppression and Radiation Resistance. Cancers (Basel) 2020;12:E3853. [PMID: 33419318 DOI: 10.3390/cancers12123853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
110 Duval KEA, Wagner RJ, Beiss V, Fiering SN, Steinmetz NF, Hoopes PJ. Cowpea Mosaic Virus Nanoparticle Enhancement of Hypofractionated Radiation in a B16 Murine Melanoma Model. Front Oncol 2020;10:594614. [PMID: 33392089 DOI: 10.3389/fonc.2020.594614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 Kwon YS, Lee MG, Baek J, Nam KS, Lee JI, Kim S, Jang H. Evaluation of Radiotherapy-Induced Systemic Antitumor Effects in Mice Bearing 4T1 Mouse Breast Cancer Cells. Cancer Biother Radiopharm 2020. [PMID: 33259733 DOI: 10.1089/cbr.2020.3958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Deipolyi AR, Johnson CB, Erinjeri JP, Bryce YC. Combination Therapies with Y90: Immunoradiation. Digestive Disease Interventions 2020;04:382-8. [DOI: 10.1055/s-0040-1721454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Pohanková D, Kopecký J. Radiotherapy and immunotherapy are irreplaceable in the treatment of cancer. Onkologie 2020;14:213-218. [DOI: 10.36290/xon.2020.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Chen H, Luan X, Paholak HJ, Burnett JP, Stevers NO, Sansanaphongpricha K, He M, Chang AE, Li Q, Sun D. Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomedicine (Lond) 2020;15:77-92. [PMID: 31868112 DOI: 10.2217/nnm-2019-0190] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
115 Paris ND, Kallenbach JG, Bachman JF, Blanc RS, Johnston CJ, Hernady E, Williams JP, Chakkalakal JV. Chemoradiation impairs myofiber hypertrophic growth in a pediatric tumor model. Sci Rep 2020;10:19501. [PMID: 33177579 DOI: 10.1038/s41598-020-75913-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
116 Chen H, Louie A, Higginson D, Palma D, Colaco R, Sahgal A. Stereotactic Radiosurgery and Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. Clinical Oncology 2020;32:713-27. [DOI: 10.1016/j.clon.2020.06.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
117 Plavc G, Jesenko T, Oražem M, Strojan P. Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer. Cancers (Basel) 2020;12:E3197. [PMID: 33143094 DOI: 10.3390/cancers12113197] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
118 Ji D, Song C, Li Y, Xia J, Wu Y, Jia J, Cui X, Yu S, Gu J. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. J Immunother Cancer 2020;8:e000826. [PMID: 33106387 DOI: 10.1136/jitc-2020-000826] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
119 Wang X, Lou Z, Zhang L, Liu Z, Zhang J, Gao J, Ji Y. Evaluation of the prognostic value of derived neutrophil/lymphocyte ratio in early stage non-small cell lung cancer patients treated with stereotactic ablative radiotherapy. Medicine (Baltimore) 2020;99:e22603. [PMID: 33080694 DOI: 10.1097/MD.0000000000022603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
120 Krisnawan VE, Stanley JA, Schwarz JK, DeNardo DG. Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance. Cancers (Basel) 2020;12:E2916. [PMID: 33050580 DOI: 10.3390/cancers12102916] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
121 Shirasawa M, Yoshida T, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. Eur J Cancer 2020;140:28-36. [PMID: 33039811 DOI: 10.1016/j.ejca.2020.08.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
122 Linares-Galiana I, Berenguer-Frances MA, Cañas-Cortés R, Pujol-Canadell M, Comas-Antón S, Martínez E, Laplana M, Pérez-Montero H, Pla-Farnós MJ, Navarro-Martin A, Nuñez M, Both B, Guedea F. Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer. J Radiat Res 2021;62:110-8. [PMID: 33006364 DOI: 10.1093/jrr/rraa083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
123 Xia WY, Feng W, Zhang CC, Shen YJ, Zhang Q, Yu W, Cai XW, Fu XL. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res 2020;9:2120-36. [PMID: 33209631 DOI: 10.21037/tlcr-20-827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
124 Winge‐main AK, Wälchli S, Inderberg EM. T cell receptor therapy against melanoma—Immunotherapy for the future? Scand J Immunol 2020;92. [DOI: 10.1111/sji.12927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
125 Guo H, Bai R, Cui J. [Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:101-10. [PMID: 32093454 DOI: 10.3779/j.issn.1009-3419.2020.02.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
126 Lubas MJ, Kumar SS. The Combined Use of SBRT and Immunotherapy—a Literature Review. Curr Oncol Rep 2020;22. [DOI: 10.1007/s11912-020-00986-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
127 Ni K, Luo T, Nash GT, Lin W. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy. Acc Chem Res 2020;53:1739-48. [PMID: 32808760 DOI: 10.1021/acs.accounts.0c00313] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 22.3] [Reference Citation Analysis]
128 Daro-Faye M, Kassouf W, Souhami L, Marcq G, Cury F, Niazi T, Sargos P. Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World J Urol 2021;39:1331-43. [PMID: 32915313 DOI: 10.1007/s00345-020-03440-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
129 Osei E, Francis R, Sheraz L. A review of radiation induced abscopal effect: combining radiotherapy and immunotherapy to treat the untreated distant metastatic tumours. J Radiother Pract 2022;21:117-24. [DOI: 10.1017/s1460396920000680] [Reference Citation Analysis]
130 Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M, Rieken S. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer 2020;20:806. [PMID: 32842974 DOI: 10.1186/s12885-020-07264-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
131 Duval KEA, Petryk JD, Crary-Burney MA, Demidenko E, Wagner RJ, Hoopes PJ. mNP hyperthermia and hypofractionated radiation activate similar immunogenetic and cytotoxic pathways. Int J Hyperthermia 2020;37:929-37. [PMID: 32757666 DOI: 10.1080/02656736.2020.1802070] [Reference Citation Analysis]
132 Cao Y, Li W, Wang Z, Pang H. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. Tumori 2021;107:282-91. [PMID: 32734832 DOI: 10.1177/0300891620940382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
133 Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol 2020;13:105. [PMID: 32723363 DOI: 10.1186/s13045-020-00940-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
134 Gadwa J, Karam SD. Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer. Int J Radiat Oncol Biol Phys 2020;108:46-55. [PMID: 32629082 DOI: 10.1016/j.ijrobp.2020.06.067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
135 Zhong XF, Sun X. Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy. Acta Pharmacol Sin 2020;41:928-35. [PMID: 32355277 DOI: 10.1038/s41401-020-0414-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
136 Li S, Shen L. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. J Cancer 2020;11:5056-68. [PMID: 32742453 DOI: 10.7150/jca.44408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
137 Wang X, Zhao Z, Wang P, Geng X, Zhu L, Li M. Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients. Front Oncol 2020;10:997. [PMID: 32656085 DOI: 10.3389/fonc.2020.00997] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
138 Chen J, Liu X, Zeng Z, Li J, Luo Y, Sun W, Gong Y, Zhang J, Wu Q, Xie C. Immunomodulation of NK Cells by Ionizing Radiation. Front Oncol 2020;10:874. [PMID: 32612950 DOI: 10.3389/fonc.2020.00874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
139 Garelli E, Rittmeyer A, Putora PM, Glatzer M, Dressel R, Andreas S. Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy 2019;11:1445-61. [PMID: 31826745 DOI: 10.2217/imt-2019-0105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
140 Neophytou CM, Pierides C, Christodoulou MI, Costeas P, Kyriakou TC, Papageorgis P. The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. Front Oncol 2020;10:899. [PMID: 32656079 DOI: 10.3389/fonc.2020.00899] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
141 Wang X, Wang P, Zhao Z, Mao Q, Yu J, Li M. A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Ther Adv Med Oncol 2020;12:1758835920926822. [PMID: 32518598 DOI: 10.1177/1758835920926822] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
142 Rouanet J, Benboubker V, Akil H, Hennino A, Auzeloux P, Besse S, Pereira B, Delorme S, Mansard S, D'Incan M, Degoul F, Rouzaire PO. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy. Cancer Immunol Immunother 2020;69:2075-88. [PMID: 32447411 DOI: 10.1007/s00262-020-02606-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
143 Berghen C, Joniau S, Vulsteke C, Albersen M, Devos G, Rans K, Haustermans K, De Meerleer G. Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancermedicalscience 2020;14:1036. [PMID: 32565889 DOI: 10.3332/ecancer.2020.1036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
144 Figura NB, Oliver DE, Mohammadi H, Martinez K, Grass GD, Hoffe SE, Johnstone PAS, Frakes JM. Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution Experience. Am J Clin Oncol 2020;43:107-14. [PMID: 31764023 DOI: 10.1097/COC.0000000000000634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
145 Piper M, Mueller AC, Karam SD. The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy. Mol Carcinog 2020;59:754-65. [PMID: 32363633 DOI: 10.1002/mc.23205] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
146 Wang X, Wang F, Zhong M, Yarden Y, Fu L. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer 2020;19:81. [PMID: 32359357 DOI: 10.1186/s12943-020-01200-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Wang X, Wang F, Zhong M, Yarden Y, Fu L. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer 2020;19:81. [PMID: 32359357 DOI: 10.1186/s12943-020-01200-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 12.7] [Reference Citation Analysis]
148 Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 2020;5:60. [PMID: 32355263 DOI: 10.1038/s41392-020-0150-x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 217] [Article Influence: 66.3] [Reference Citation Analysis]
149 Tubin S, Yan W, Mourad WF, Fossati P, Khan MK. The future of radiation-induced abscopal response: beyond conventional radiotherapy approaches. Future Oncol 2020;16:1137-51. [PMID: 32338046 DOI: 10.2217/fon-2020-0063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
150 Alinezhad M, Bakhshandeh M, Rostami E, Alimohamadi R, Mosaffa N, Jalali SA. Synergistic effects of anti-PDL-1 with ablative radiation comparing to other regimens with same biological effect dose based on different immunogenic response. PLoS One 2020;15:e0231507. [PMID: 32287292 DOI: 10.1371/journal.pone.0231507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
151 Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol 2020;25:801-9. [PMID: 32246277 DOI: 10.1007/s10147-020-01666-1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 23.3] [Reference Citation Analysis]
152 Nesseler JP, Lee MH, Nguyen C, Kalbasi A, Sayre JW, Romero T, Nickers P, McBride WH, Schaue D. Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy. Cancers (Basel) 2020;12:E714. [PMID: 32197352 DOI: 10.3390/cancers12030714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
153 Lin LL, Lakomy DS, Ning MS, Simpkins F, Jhingran A. Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. Int J Gynecol Cancer 2020;30:409-23. [PMID: 32193219 DOI: 10.1136/ijgc-2020-001227] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
154 Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol 2020;93:20200042. [PMID: 32101479 DOI: 10.1259/bjr.20200042] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
155 Corrao G, Marvaso G, Ferrara R, Lo Russo G, Gugliandolo SG, Piperno G, Spaggiari L, De Marinis F, Orecchia R, Garassino MC, Jereczek-Fossa BA. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer 2020;142:70-9. [PMID: 32120227 DOI: 10.1016/j.lungcan.2020.02.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
156 Theelen WS, de Jong MC, Baas P. Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect. Lung Cancer 2020;142:106-13. [PMID: 32126451 DOI: 10.1016/j.lungcan.2020.02.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
157 Abbassi LM, Cao KI, Kirova YM. [Immunotherapy and radiotherapy for management of breast cancer: Rational and overview on clinical practice]. Cancer Radiother 2020;24:73-80. [PMID: 32046913 DOI: 10.1016/j.canrad.2019.06.019] [Reference Citation Analysis]
158 Wennerberg E, Spada S, Rudqvist NP, Lhuillier C, Gruber S, Chen Q, Zhang F, Zhou XK, Gross SS, Formenti SC, Demaria S. CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection. Cancer Immunol Res 2020;8:465-78. [PMID: 32047024 DOI: 10.1158/2326-6066.CIR-19-0449] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
159 Liu J, Xu C, Zhu J, Sivik J, Drabick JJ, Mackley HB. Identifying the Optimal Fractionation Schedules for Improved Response Rates and Survival in Patients with Metastatic Melanoma Treated with Ipilimumab and Radiotherapy. CCTR 2020;16:78-85. [DOI: 10.2174/2542584601666180326111906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Seyedin SN, Hasibuzzaman MM, Pham V, Petronek MS, Callaghan C, Kalen AL, Mapuskar KA, Mott SL, Spitz DR, Allen BG, Caster JM. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models. Int J Radiat Oncol Biol Phys 2020;108:81-92. [PMID: 32036006 DOI: 10.1016/j.ijrobp.2020.01.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
161 Sun J, Zhang A, Li W, Wang Q, Li D, Zhang D, Duan X. Biologically effective dose (BED) escalation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma patients (≤5 cm) with CyberKnife: protocol of study. Radiat Oncol 2020;15:20. [PMID: 31992327 DOI: 10.1186/s13014-020-1471-1] [Reference Citation Analysis]
162 Yang L, Liu L, Wu X, Guo X, Yang Y, Wang T. Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: A meta-analysis. Int Immunopharmacol 2020;80:106148. [PMID: 31978802 DOI: 10.1016/j.intimp.2019.106148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
163 Wang C, Park J, Ouyang C, Longmate JA, Tajon M, Chao J, Lim D, Sandhu J, Yin HH, Pillai R, Gozo MC, Avalos C, Egelston CA, Lee PP, Fakih M. A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. Oncologist 2020;25:382-e776. [PMID: 31857446 DOI: 10.1634/theoncologist.2019-0924] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
164 Spaas M, Lievens Y. Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach? Front Med (Lausanne). 2019;6:244. [PMID: 31788476 DOI: 10.3389/fmed.2019.00244] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
165 Huang W, Fan Y, Cheng X, Liang H, Pan H, Xiao T, Chen M, Guan J. A preliminary Study on the Effect of Head and Neck Chemoradiotherapy on Systematic Immunity. Dose Response 2019;17:1559325819884186. [PMID: 31695581 DOI: 10.1177/1559325819884186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
166 Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;. [PMID: 31294749 DOI: 10.1001/jamaoncol.2019.1478] [Cited by in Crossref: 362] [Cited by in F6Publishing: 409] [Article Influence: 90.5] [Reference Citation Analysis]
167 Sun J, Zhang T, Wang J, Li W, Zhang A, He W, Zhang D, Li D, Ding J, Duan X. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm). BMC Cancer 2019;19:846. [PMID: 31455251 DOI: 10.1186/s12885-019-6063-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
168 Goto T. Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. Vaccines (Basel) 2019;7:E100. [PMID: 31455032 DOI: 10.3390/vaccines7030100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
169 Tazawa H, Suzuki T, Komo T, Kubota H, Tahara S, Sada H, Hadano N, Shimizu W, Ishiyama K, Onoe T, Sudo T, Shimizu Y, Tashiro H. A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab. Case Rep Oncol 2019;12:523-8. [PMID: 31427946 DOI: 10.1159/000501717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
170 Jones KI, Tiersma J, Yuzhalin AE, Gordon-Weeks AN, Buzzelli J, Im JH, Muschel RJ. Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol Med 2018;10:e9342. [PMID: 30442705 DOI: 10.15252/emmm.201809342] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
171 Bernichon E, Espenel S, Méry B, Trone JC, Rehalia-Blanchard A, He YM, Rancoule C, Magné N. [HPV: Carcinogenic implications and preventive measures]. Presse Med 2019;48:756-66. [PMID: 31307878 DOI: 10.1016/j.lpm.2019.05.019] [Reference Citation Analysis]
172 Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer. 2019;7:160. [PMID: 31238970 DOI: 10.1186/s40425-019-0634-9] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 18.5] [Reference Citation Analysis]
173 Lockney NA, Zhang M, Morris CG, Nichols RC, Okunieff P, Swarts S, Zhang Z, Zhang B, Zhang A, Hoppe BS. Radiation-induced tumor immunity in patients with non-small cell lung cancer. Thorac Cancer 2019;10:1605-11. [PMID: 31228354 DOI: 10.1111/1759-7714.13122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
174 Boustani J, Grapin M, Laurent PA, Apetoh L, Mirjolet C. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers (Basel) 2019;11:E860. [PMID: 31226866 DOI: 10.3390/cancers11060860] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
175 Brokāne L, Jaunalksne I, Tilgase A, Olmane E, Petroška D, Rasa A, Alberts P. Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient. Clin Case Rep 2019;7:1191-6. [PMID: 31183092 DOI: 10.1002/ccr3.2182] [Reference Citation Analysis]
176 Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid 2018;28:739-47. [PMID: 29774792 DOI: 10.1089/thy.2017.0706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
177 Kreidieh M, Zeidan YH, Shamseddine A. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. J Oncol. 2019;2019:4304817. [PMID: 31182960 DOI: 10.1155/2019/4304817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
178 Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater 2019;4:398-414. [DOI: 10.1038/s41578-019-0108-1] [Cited by in Crossref: 416] [Cited by in F6Publishing: 426] [Article Influence: 104.0] [Reference Citation Analysis]
179 de Leve S, Wirsdörfer F, Jendrossek V. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. Front Immunol 2019;10:698. [PMID: 31024543 DOI: 10.3389/fimmu.2019.00698] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
180 Shevtsov M, Sato H, Multhoff G, Shibata A. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. Front Oncol 2019;9:156. [PMID: 30941308 DOI: 10.3389/fonc.2019.00156] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 18.5] [Reference Citation Analysis]
181 Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson JM. Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Front Oncol 2019;9:122. [PMID: 30895168 DOI: 10.3389/fonc.2019.00122] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
182 Rajani KR, Carlstrom LP, Parney IF, Johnson AJ, Warrington AE, Burns TC. Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. Front Oncol 2018;8:656. [PMID: 30854331 DOI: 10.3389/fonc.2018.00656] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
183 Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol 2019;10:193. [PMID: 30828330 DOI: 10.3389/fimmu.2019.00193] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
184 Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019;7:38. [PMID: 30736848 DOI: 10.1186/s40425-019-0520-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 17.3] [Reference Citation Analysis]
185 Darragh LB, Oweida AJ, Karam SD. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment. Front Immunol 2018;9:3154. [PMID: 30766539 DOI: 10.3389/fimmu.2018.03154] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 14.3] [Reference Citation Analysis]
186 Leaman Alcibar O, Candini D, López-Campos F, Albert Antequera M, Morillo Macías V, Conde AJ, Rodríguez Pérez A, Hervás Morón A, Contreras Martínez J, Ferrer Albiach C, Navarro Aguilar S, Rodríguez-Ruiz ME. Time for radioimmunotherapy: an overview to bring improvements in clinical practice. Clin Transl Oncol 2019;21:992-1004. [PMID: 30644044 DOI: 10.1007/s12094-018-02027-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
187 Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? Front Immunol 2018;9:3107. [PMID: 30692993 DOI: 10.3389/fimmu.2018.03107] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
188 Choy H, Mendel JT. Management of Locally Advanced Lung Cancer. Pulmonary Adenocarcinoma: Approaches to Treatment 2019. [DOI: 10.1016/b978-0-323-55433-6.00004-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
189 Savage T, Guha C. Radio-Immunology of Ablative Radiation. Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy 2019. [DOI: 10.1007/978-3-030-16924-4_2] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
190 Travers JB. Platelet-Activating Factor as an Effector for Environmental Stressors. Handb Exp Pharmacol 2020;259:185-203. [PMID: 31087194 DOI: 10.1007/164_2019_218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
191 Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quiñones-hinojosa A, Zaorsky NG, Trifiletti DM. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiotherapy and Oncology 2019;130:104-12. [DOI: 10.1016/j.radonc.2018.08.025] [Cited by in Crossref: 121] [Cited by in F6Publishing: 131] [Article Influence: 30.3] [Reference Citation Analysis]
192 Wu CT, Chen WC, Chen MF. The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation. Cancers (Basel) 2018;11:E20. [PMID: 30587810 DOI: 10.3390/cancers11010020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
193 Wang SJ, Haffty B. Radiotherapy as a New Player in Immuno-Oncology. Cancers (Basel). 2018;10. [PMID: 30558196 DOI: 10.3390/cancers10120515] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
194 Buchwald ZS, Wynne J, Nasti TH, Zhu S, Mourad WF, Yan W, Gupta S, Khleif SN, Khan MK. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation. Front Oncol 2018;8:612. [PMID: 30619752 DOI: 10.3389/fonc.2018.00612] [Cited by in Crossref: 91] [Cited by in F6Publishing: 101] [Article Influence: 18.2] [Reference Citation Analysis]
195 Carvalho HA, Villar RC. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo) 2018;73:e557s. [PMID: 30540123 DOI: 10.6061/clinics/2018/e557s] [Cited by in Crossref: 74] [Cited by in F6Publishing: 90] [Article Influence: 14.8] [Reference Citation Analysis]
196 Navarro-Martín A, Galiana IL, Berenguer Frances MA, Cacicedo J, Cañas Cortés R, Comas Anton S, Padrones Sánchez S, Bolívar Cuevas S, Parry R, Guedea Edo F. Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis. Int J Mol Sci 2018;19:E3963. [PMID: 30544863 DOI: 10.3390/ijms19123963] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
197 Nesseler JP, Schaue D, McBride WH, Lee MH, Kaprealian T, Niclou SP, Nickers P. Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. Adv Radiat Oncol 2019;4:268-82. [PMID: 31011672 DOI: 10.1016/j.adro.2018.11.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
198 Duan X, Chan C, Lin W. Durch Nanopartikel vermittelter immunogener Zelltod ermöglicht und verstärkt die Immuntherapie gegen Krebs. Angew Chem 2019;131:680-91. [DOI: 10.1002/ange.201804882] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
199 Duan X, Chan C, Lin W. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. Angew Chem Int Ed Engl 2019;58:670-80. [PMID: 30016571 DOI: 10.1002/anie.201804882] [Cited by in Crossref: 374] [Cited by in F6Publishing: 393] [Article Influence: 74.8] [Reference Citation Analysis]
200 Routman DM, Yan E, Vora S, Peterson J, Mahajan A, Chaichana KL, Laack N, Brown PD, Parney IF, Burns TC, Trifiletti DM. Preoperative Stereotactic Radiosurgery for Brain Metastases. Front Neurol 2018;9:959. [PMID: 30542316 DOI: 10.3389/fneur.2018.00959] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
201 Formenti SC. Optimizing Dose Per Fraction: A New Chapter in the Story of the Abscopal Effect? Int J Radiat Oncol Biol Phys 2017;99:677-9. [PMID: 29280462 DOI: 10.1016/j.ijrobp.2017.07.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
202 Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 2019;16:123-35. [DOI: 10.1038/s41571-018-0119-7] [Cited by in Crossref: 142] [Cited by in F6Publishing: 155] [Article Influence: 28.4] [Reference Citation Analysis]
203 Krombach J, Hennel R, Brix N, Orth M, Schoetz U, Ernst A, Schuster J, Zuchtriegel G, Reichel CA, Bierschenk S, Sperandio M, Vogl T, Unkel S, Belka C, Lauber K. Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology 2019;8:e1523097. [PMID: 30546963 DOI: 10.1080/2162402X.2018.1523097] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
204 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
205 Markovsky E, Budhu S, Samstein RM, Li H, Russell J, Zhang Z, Drill E, Bodden C, Chen Q, Powell SN, Merghoub T, Wolchok JD, Humm J, Deasy JO, Haimovitz-Friedman A. An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. Int J Radiat Oncol Biol Phys 2019;103:697-708. [PMID: 30342090 DOI: 10.1016/j.ijrobp.2018.10.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
206 Kim JH, Jenrow KA, Brown SL. Novel biological strategies to enhance the radiation therapeutic ratio. Radiat Oncol J 2018;36:172-81. [PMID: 30309208 DOI: 10.3857/roj.2018.00332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
207 McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mamm Genome 2018;29:843-65. [PMID: 30178305 DOI: 10.1007/s00335-018-9777-0] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 16.2] [Reference Citation Analysis]
208 Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S. A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. J Radiat Oncol 2018;7:223-232. [DOI: 10.1007/s13566-018-0351-x] [Reference Citation Analysis]
209 Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104. [PMID: 30115069 DOI: 10.1186/s13045-018-0647-8] [Cited by in Crossref: 172] [Cited by in F6Publishing: 188] [Article Influence: 34.4] [Reference Citation Analysis]
210 Serre R, Barlesi F, Muracciole X, Barbolosi D. Immunologically effective dose: a practical model for immuno-radiotherapy. Oncotarget 2018;9:31812-9. [PMID: 30159124 DOI: 10.18632/oncotarget.25746] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
211 Stea B, Skrepnik T, Hsu CC, Abendroth R. The role of radiation therapy in the treatment of metastatic cancer. Clin Exp Metastasis. 2018;35:535-546. [PMID: 30062507 DOI: 10.1007/s10585-018-9926-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
212 Fuentes-Antrás J, Provencio M, Díaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev 2018;70:16-21. [PMID: 30053725 DOI: 10.1016/j.ctrv.2018.07.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 14.2] [Reference Citation Analysis]
213 Choi J, Beaino W, Fecek RJ, Fabian KPL, Laymon CM, Kurland BF, Storkus WJ, Anderson CJ. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. J Nucl Med 2018;59:1843-9. [PMID: 29959213 DOI: 10.2967/jnumed.118.209510] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
214 Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo N, La Riviere P, Weichselbaum RR, Lin W. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 2018;9:2351. [PMID: 29907739 DOI: 10.1038/s41467-018-04703-w] [Cited by in Crossref: 176] [Cited by in F6Publishing: 187] [Article Influence: 35.2] [Reference Citation Analysis]
215 Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 2018;6:46. [PMID: 29866197 DOI: 10.1186/s40425-018-0361-7] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 16.6] [Reference Citation Analysis]
216 Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249-279. [PMID: 29027221 DOI: 10.1111/imr.12573] [Cited by in Crossref: 105] [Cited by in F6Publishing: 115] [Article Influence: 21.0] [Reference Citation Analysis]
217 Durante M, Formenti SC. Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. Front Oncol 2018;8:192. [PMID: 29911071 DOI: 10.3389/fonc.2018.00192] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 13.8] [Reference Citation Analysis]
218 Wennerberg E, Vanpouille-Box C, Bornstein S, Yamazaki T, Demaria S, Galluzzi L. Immune recognition of irradiated cancer cells. Immunol Rev 2017;280:220-30. [PMID: 29027232 DOI: 10.1111/imr.12568] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
219 Sathianathen NJ, Krishna S, Konety BR, Griffith TS. The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer. Immunotherapy 2017;9:1005-18. [PMID: 28971750 DOI: 10.2217/imt-2017-0051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
220 Spirou SV, Costa Lima SA, Bouziotis P, Vranješ-Djurić S, Efthimiadou EΚ, Laurenzana A, Barbosa AI, Garcia-Alonso I, Jones C, Jankovic D, Gobbo OL. Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy. Nanomaterials (Basel) 2018;8:E306. [PMID: 29734795 DOI: 10.3390/nano8050306] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
221 Benveniste MF, Welsh J, Viswanathan C, Shroff GS, Betancourt Cuellar SL, Carter BW, Marom EM. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. Radiol Clin North Am 2018;56:471-83. [PMID: 29622079 DOI: 10.1016/j.rcl.2018.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
222 Du D, Song T, Dai H, Jing Z, Chen P, Wu S. Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients. Oncoimmunology 2018;7:e1450128. [PMID: 30221039 DOI: 10.1080/2162402X.2018.1450128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
223 Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, Miller R, Nugent K, Shinder B, Tosoian J, Fuchs EJ, Tran PT, Hurley PJ, Vuica-Ross M, Schaeffer EM, Drake CG, Ross AE. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis 2018;21:126-36. [PMID: 29556048 DOI: 10.1038/s41391-018-0035-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
224 Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology 2018;7:e1440168. [PMID: 29900043 DOI: 10.1080/2162402X.2018.1440168] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
225 Yuan C, Wang Q. Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients. Clin Transl Oncol 2018;20:1219-25. [PMID: 29536332 DOI: 10.1007/s12094-018-1851-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
226 Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Dicker AP, Mourtada F, Sims-Mourtada J. The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. Cancer Growth Metastasis. 2018;11:1179064418761639. [PMID: 29551910 DOI: 10.1177/1179064418761639] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 15.4] [Reference Citation Analysis]
227 Moskovitz J, Moy J, Ferris RL. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oncol Rep 2018;20:22. [PMID: 29502288 DOI: 10.1007/s11912-018-0654-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 81] [Article Influence: 14.0] [Reference Citation Analysis]
228 Sundahl N, De Wolf K, Kruse V, Meireson A, Reynders D, Goetghebeur E, Van Gele M, Speeckaert R, Hennart B, Brochez L, Ost P. Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma. International Journal of Radiation Oncology*Biology*Physics 2018;100:906-15. [DOI: 10.1016/j.ijrobp.2017.11.029] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
229 Deng G, Hu P, Zhang J, Liu Q, Liang N, Xie J, Qiao L, Luo H, Xu D, Liu F, Yu X, Liu Z, Lv Y, Zhang J. Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer. Oncotarget 2016;7:85142-50. [PMID: 27835886 DOI: 10.18632/oncotarget.13202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
230 Morisada M, Chamberlin M, Allen C. Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. Head Neck 2018;40:1321-34. [PMID: 29461655 DOI: 10.1002/hed.25101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
231 Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 2018;36:1611-8. [PMID: 29437535 DOI: 10.1200/JCO.2017.76.2229] [Cited by in Crossref: 301] [Cited by in F6Publishing: 331] [Article Influence: 60.2] [Reference Citation Analysis]
232 Zhang X, Niedermann G. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. Int J Radiat Oncol Biol Phys 2018;101:63-73. [PMID: 29534901 DOI: 10.1016/j.ijrobp.2018.01.094] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 9.4] [Reference Citation Analysis]
233 Agustoni F, Hirsch FR. PACIFIC trial: new perspectives for immunotherapy in lung cancer. Transl Lung Cancer Res 2018;7:S19-24. [PMID: 29531898 DOI: 10.21037/tlcr.2017.12.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
234 Wang HH, Wu ZQ, Qian D, Zaorsky NG, Qiu MH, Cheng JJ, Jiang C, Wang J, Zeng XL, Liu CL, Tian LJ, Ying GG, Meng MB, Hao XS, Yuan ZY. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. Int J Radiat Oncol Biol Phys 2018;101:49-62. [PMID: 29619976 DOI: 10.1016/j.ijrobp.2018.01.036] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
235 Sahu RP, Harrison KA, Weyerbacher J, Murphy RC, Konger RL, Garrett JE, Chin-Sinex HJ, Johnston ME 2nd, Dynlacht JR, Mendonca M, McMullen K, Li G, Spandau DF, Travers JB. Radiation therapy generates platelet-activating factor agonists. Oncotarget 2016;7:20788-800. [PMID: 26959112 DOI: 10.18632/oncotarget.7878] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
236 Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol 2018;10:1758834017742575. [PMID: 29383033 DOI: 10.1177/1758834017742575] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 23.0] [Reference Citation Analysis]
237 Basler L, Kowalczyk A, Heidenreich R, Fotin-Mleczek M, Tsitsekidis S, Zips D, Eckert F, Huber SM. Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. Cancer Immunol Immunother 2018;67:653-62. [PMID: 29335856 DOI: 10.1007/s00262-018-2117-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
238 Rekers NH, Olivo Pimentel V, Yaromina A, Lieuwes NG, Biemans R, Zegers CML, Germeraad WTV, Van Limbergen EJ, Neri D, Dubois LJ, Lambin P. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Oncoimmunology 2018;7:e1414119. [PMID: 29632732 DOI: 10.1080/2162402X.2017.1414119] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
239 Zhang I, Yamamoto M, Knisely JPS. Multiple Brain Metastases. Adult CNS Radiation Oncology 2018. [DOI: 10.1007/978-3-319-42878-9_32] [Reference Citation Analysis]
240 Joe MB, Lum JJ, Watson PH, Tonseth RP, McGhie JP, Truong PT. Radiation generates an abscopal response and complete resolution of metastatic squamous cell carcinoma of the anal canal: a case report. J Gastrointest Oncol 2017;8:E84-9. [PMID: 29299375 DOI: 10.21037/jgo.2017.06.15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
241 Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. Cancer Immunol Res 2018;6:139-50. [PMID: 29180535 DOI: 10.1158/2326-6066.CIR-17-0134] [Cited by in Crossref: 129] [Cited by in F6Publishing: 133] [Article Influence: 21.5] [Reference Citation Analysis]
242 Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C, Hodge JW, Mitchell JB, Friedman J, Allen CT. PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology 2018;7:e1395996. [PMID: 29399393 DOI: 10.1080/2162402X.2017.1395996] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
243 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
244 Son CH, Fleming GF, Moroney JW. Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. Cancer Manag Res 2017;9:553-63. [PMID: 29184441 DOI: 10.2147/CMAR.S116683] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
245 Aboudaram A, Modesto A, Chaltiel L, Gomez-roca C, Boulinguez S, Sibaud V, Delord J, Chira C, Delannes M, Moyal E, Meyer N. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. Melanoma Research 2017;27:485-91. [DOI: 10.1097/cmr.0000000000000386] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 12.2] [Reference Citation Analysis]
246 Tubin S, Raunik W. Hunting for abscopal and bystander effects: clinical exploitation of non-targeted effects induced by partial high-single-dose irradiation of the hypoxic tumour segment in oligometastatic patients. Acta Oncol 2017;56:1333-9. [PMID: 28686524 DOI: 10.1080/0284186X.2017.1346385] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
247 Kumar SS, Higgins KA, McGarry RC. Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. Front Oncol 2017;7:197. [PMID: 28929083 DOI: 10.3389/fonc.2017.00197] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
248 Manapov F, Roengvoraphoj O, Eze C. Why is survival after pembrolizumab affected by previous radiotherapy? The Lancet Oncology 2017;18:e504. [DOI: 10.1016/s1470-2045(17)30472-2] [Reference Citation Analysis]
249 Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J 2016;22:257-66. [PMID: 27441745 DOI: 10.1097/PPO.0000000000000210] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
250 Moding EJ, Mowery YM, Kirsch DG. Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. Cancer J 2016;22:267-73. [PMID: 27441746 DOI: 10.1097/PPO.0000000000000203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
251 Koonce NA, Juratli MA, Cai C, Sarimollaoglu M, Menyaev YA, Dent J, Quick CM, Dings RPM, Nedosekin D, Zharov V, Griffin RJ. Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry. Biochem Biophys Res Commun 2017;492:507-12. [PMID: 28822765 DOI: 10.1016/j.bbrc.2017.08.053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
252 Zhang J, Kong L, Jiao Q, Li M, Yu J. Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead. Cancer Lett 2017;401:46-52. [PMID: 28526616 DOI: 10.1016/j.canlet.2017.04.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
253 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
254 Irenaeus S, Schiza A, Mangsbo SM, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlström H, Tötterman TH, Loskog A, Ullenhag GJ. Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. Oncotarget 2017;8:78573-87. [PMID: 29108250 DOI: 10.18632/oncotarget.19750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
255 Herskind C, Wenz F, Giordano FA. Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol 2017;7:147. [PMID: 28791250 DOI: 10.3389/fonc.2017.00147] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
256 McBride WH, Ganapathy E, Lee MH, Nesseler JP, Nguyen C, Schaue D. A perspective on the impact of radiation therapy on the immune rheostat. Br J Radiol 2017;90:20170272. [PMID: 28707537 DOI: 10.1259/bjr.20170272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
257 Shen MJ, Xu LJ, Yang L, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y. Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway. Oncotarget 2017;8:80506-20. [PMID: 29113321 DOI: 10.18632/oncotarget.19193] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
258 Zhang T, Yu H, Ni C, Zhang T, Liu L, Lv Q, Zhang Z, Wang Z, Wu D, Wu P, Chen G, Wang L, Wei Q, Huang J, Wang X. Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci Rep 2017;7:4866. [PMID: 28687760 DOI: 10.1038/s41598-017-04978-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
259 Xie G, Gu D, Zhang L, Chen S, Wu D. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. Cancer Biol Ther 2017;18:547-51. [PMID: 28665741 DOI: 10.1080/15384047.2017.1345389] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
260 Dolgin E. Radiation redux. Proc Natl Acad Sci U S A 2017;114:6416-6420. [DOI: 10.1073/pnas.1707802114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
261 Nesseler J, Peiffert D, Vogin G, Nickers P. Cancer, radiothérapie et système immunitaire. Cancer/Radiothérapie 2017;21:307-15. [DOI: 10.1016/j.canrad.2017.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
262 Van Limbergen EJ, De Ruysscher DK, Olivo Pimentel V, Marcus D, Berbee M, Hoeben A, Rekers N, Theys J, Yaromina A, Dubois LJ, Lambin P. Combining radiotherapy with immunotherapy: the past, the present and the future. Br J Radiol. 2017;90:20170157. [PMID: 28541096 DOI: 10.1259/bjr.20170157] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
263 Baues C, Trommer-Nestler M, Jablonska K, Bröckelmann PJ, Schlaak M, von Bergwelt-Baildon M, Engert A, Semrau R, Marnitz S, Theurich S. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. Immunotherapy 2017;9:423-33. [PMID: 28357914 DOI: 10.2217/imt-2017-0002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
264 Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, Antonia SJ, Caudell JJ, Harrison LB, Sahebjam S, Gray JE, Etame AB, Johnstone PA, Yu M, Perez BA. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol 2017;133:331-8. [DOI: 10.1007/s11060-017-2437-5] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 13.0] [Reference Citation Analysis]
265 Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG, Harrison LB. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol 2017;18:e266-73. [PMID: 28456586 DOI: 10.1016/S1470-2045(17)30252-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 117] [Article Influence: 18.5] [Reference Citation Analysis]
266 LaPlant Q, Deselm C, Lockney NA, Hsieh J, Yamada Y. Potential abscopal response to dual checkpoint blockade in RCC after reirradiation using dose-painting SBRT. Pract Radiat Oncol 2017;7:396-9. [PMID: 28551390 DOI: 10.1016/j.prro.2017.04.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
267 Schaue D. A Century of Radiation Therapy and Adaptive Immunity. Front Immunol. 2017;8:431. [PMID: 28443099 DOI: 10.3389/fimmu.2017.00431] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
268 Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. Int J Clin Oncol 2017;22:690-7. [PMID: 28382561 DOI: 10.1007/s10147-017-1118-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
269 Janiak MK, Wincenciak M, Cheda A, Nowosielska EM, Calabrese EJ. Cancer immunotherapy: how low-level ionizing radiation can play a key role. Cancer Immunol Immunother 2017;66:819-32. [PMID: 28361232 DOI: 10.1007/s00262-017-1993-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
270 Stankevicius V, Kuodyte K, Schveigert D, Bulotiene D, Paulauskas T, Daniunaite K, Suziedelis K. Gene and miRNA expression profiles of mouse Lewis lung carcinoma LLC1 cells following single or fractionated dose irradiation. Oncol Lett 2017;13:4190-200. [PMID: 28599420 DOI: 10.3892/ol.2017.5877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
271 Lesueur P, Chevalier F, Stefan D, Habrand JL, Lerouge D, Gervais R. Review of the mechanisms involved in the abscopal effect and future directions with a focus on thymic carcinoma. Tumori 2017;103:217-22. [PMID: 28291902 DOI: 10.5301/tj.5000616] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
272 Maia MC, Hansen AR. A comprehensive review of immunotherapies in prostate cancer. Crit Rev Oncol Hematol 2017;113:292-303. [PMID: 28427519 DOI: 10.1016/j.critrevonc.2017.02.026] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
273 Loi M, Desideri I, Greto D, Mangoni M, Sottili M, Meattini I, Becherini C, Terziani F, Delli Paoli C, Olmetto E, Bonomo P, Livi L. Radiotherapy in the age of cancer immunology: Current concepts and future developments. Crit Rev Oncol Hematol 2017;112:1-10. [PMID: 28325250 DOI: 10.1016/j.critrevonc.2017.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
274 Chajon E, Castelli J, Marsiglia H, De Crevoisier R. The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. Crit Rev Oncol Hematol 2017;111:124-32. [PMID: 28259287 DOI: 10.1016/j.critrevonc.2017.01.017] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 12.2] [Reference Citation Analysis]
275 De Wolf K, Kruse V, Sundahl N, van Gele M, Chevolet I, Speeckaert R, Brochez L, Ost P. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med 2017;15:21. [PMID: 28137295 DOI: 10.1186/s12967-017-1123-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
276 Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, Lum JJ. Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) 2017;9:E13. [PMID: 28134800 DOI: 10.3390/cancers9020013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
277 Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer 2017;5:4. [PMID: 28116088 DOI: 10.1186/s40425-016-0204-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
278 Harrington KJ. Chemotherapy and Targeted Agents. Maxillofacial Surgery 2017. [DOI: 10.1016/b978-0-7020-6056-4.00022-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
279 Schoenhals JE, Skrepnik T, Selek U, Cortez MA, Li A, Welsh JW. Optimizing Radiotherapy with Immunotherapeutic Approaches. Advances in Experimental Medicine and Biology 2017. [DOI: 10.1007/978-3-319-53156-4_3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
280 Hao Y, Yasmin-Karim S, Moreau M, Sinha N, Sajo E, Ngwa W. Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study. Phys Med Biol 2016;61:N697-707. [PMID: 27910826 DOI: 10.1088/1361-6560/61/24/N697] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
281 Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. J Thorac Oncol 2015;10:1685-93. [PMID: 26484629 DOI: 10.1097/JTO.0000000000000686] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 5.3] [Reference Citation Analysis]
282 Ge X, Zhu H, Dai W, Sun X. Stereotactic body radiotherapy in the era of radiotherapy with immunotherapy. J Thorac Dis 2016;8:2968-70. [PMID: 28066559 DOI: 10.21037/jtd.2016.11.16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
283 Levy A, Massard C, Soria JC, Deutsch E. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016;68:156-162. [PMID: 27764686 DOI: 10.1016/j.ejca.2016.09.013] [Cited by in Crossref: 91] [Cited by in F6Publishing: 101] [Article Influence: 13.0] [Reference Citation Analysis]
284 Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R. Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunol Immunother 2017;66:281-98. [PMID: 27743027 DOI: 10.1007/s00262-016-1914-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
285 Corso CD, Bindra RS. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. Seminars in Radiation Oncology 2016;26:281-98. [DOI: 10.1016/j.semradonc.2016.06.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
286 Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications. Sci Immunol. 2016;1:28018989. [PMID: 28018989 DOI: 10.1126/sciimmunol.aag1266] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 14.6] [Reference Citation Analysis]
287 Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, Harshyne LA, Louie J, Shaw CM, Hooper DC, Lu B. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. J Hematol Oncol 2016;9:96. [PMID: 27663515 DOI: 10.1186/s13045-016-0328-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
288 Jeong H, Bok S, Hong BJ, Choi HS, Ahn GO. Radiation-induced immune responses: mechanisms and therapeutic perspectives. Blood Res 2016;51:157-63. [PMID: 27722125 DOI: 10.5045/br.2016.51.3.157] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
289 Walshaw RC, Honeychurch J, Illidge TM. Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy? Br J Radiol 2016;89:20160472. [PMID: 27556933 DOI: 10.1259/bjr.20160472] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
290 Yanagihara TK, Saadatmand HJ, Wang TJC. Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. J Neurooncol 2016;130:397-411. [DOI: 10.1007/s11060-016-2270-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
291 Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67:65-85. [PMID: 27570942 DOI: 10.3322/caac.21358] [Cited by in Crossref: 212] [Cited by in F6Publishing: 238] [Article Influence: 30.3] [Reference Citation Analysis]
292 Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology 2016;5:e1214788. [PMID: 27757312 DOI: 10.1080/2162402X.2016.1214788] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
293 Popp I, Grosu AL, Niedermann G, Duda DG. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiother Oncol 2016;120:185-94. [PMID: 27495145 DOI: 10.1016/j.radonc.2016.07.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 76] [Article Influence: 9.6] [Reference Citation Analysis]
294 Michelle Xu M, Pu Y, Weichselbaum RR, Fu YX. Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene 2017;36:585-92. [PMID: 27425593 DOI: 10.1038/onc.2016.231] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
295 Levy A, Chargari C, Marabelle A, Perfettini J, Magné N, Deutsch E. Can immunostimulatory agents enhance the abscopal effect of radiotherapy? European Journal of Cancer 2016;62:36-45. [DOI: 10.1016/j.ejca.2016.03.067] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 11.6] [Reference Citation Analysis]
296 Yang YC, Chiang CS. Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. Front Oncol 2016;6:165. [PMID: 27446811 DOI: 10.3389/fonc.2016.00165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
297 Williams JP, Calvi L, Chakkalakal JV, Finkelstein JN, O'Banion MK, Puzas E. Addressing the Symptoms or Fixing the Problem? Developing Countermeasures against Normal Tissue Radiation Injury. Radiat Res 2016;186:1-16. [PMID: 27332954 DOI: 10.1667/RR14473.1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
298 Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US. Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. Front Oncol 2016;6:141. [PMID: 27379203 DOI: 10.3389/fonc.2016.00141] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 12.9] [Reference Citation Analysis]
299 Martinov T, Fife BT. Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies. Ann Transl Med 2016;4:82. [PMID: 27004229 DOI: 10.3978/j.issn.2305-5839.2016.01.13] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
300 Vaupel P, Multhoff G. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities. Strahlenther Onkol 2016;192:279-87. [PMID: 26961686 DOI: 10.1007/s00066-016-0948-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
301 Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 2016;13:516-24. [PMID: 26951040 DOI: 10.1038/nrclinonc.2016.30] [Cited by in Crossref: 195] [Cited by in F6Publishing: 220] [Article Influence: 27.9] [Reference Citation Analysis]
302 Siva S, Kron T, Bressel M, Haas M, Mai T, Vinod S, Sasso G, Wong W, Le H, Eade T, Hardcastle N, Chesson B, Pham D, Høyer M, Montgomery R, Ball D. A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). BMC Cancer 2016;16:183. [PMID: 26944262 DOI: 10.1186/s12885-016-2227-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
303 Jing W, Li M, Zhang Y, Teng F, Han A, Kong L, Zhu H. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther 2016;9:489-502. [PMID: 26889087 DOI: 10.2147/OTT.S94993] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
304 Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-e509. [PMID: 26433823 DOI: 10.1016/s1470-2045(15)00007-8] [Cited by in Crossref: 458] [Cited by in F6Publishing: 501] [Article Influence: 65.4] [Reference Citation Analysis]
305 Cooper B, Vatner R, Golden E, Silverman J, Formenti S. The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. Current Clinical Pathology 2016. [DOI: 10.1007/978-3-319-28305-0_10] [Reference Citation Analysis]
306 Teh BS, Ishiyama H, Mai W, Thompson TC, Butler EB. Long-term outcome of a phase II trial using immunomodulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate cancer. J Radiat Oncol 2015;4:377-86. [DOI: 10.1007/s13566-015-0239-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
307 Naghavi AO, Johnstone PA, Kim S. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. Curr Probl Cancer 2016;40:38-67. [PMID: 26656977 DOI: 10.1016/j.currproblcancer.2015.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
308 Chen AC, Butler EB, Lo SS, Teh BS. Radiotherapy and the abscopal effect: insight from the past, present, and future. J Radiat Oncol 2015;4:321-330. [DOI: 10.1007/s13566-015-0223-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
309 Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z. Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer 2016;17:253-262.e5. [PMID: 26732495 DOI: 10.1016/j.cllc.2015.11.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
310 Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer 2016;40:10-24. [PMID: 26612692 DOI: 10.1016/j.currproblcancer.2015.10.003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 108] [Article Influence: 12.3] [Reference Citation Analysis]
311 Hellweg CE. The Nuclear Factor κB pathway: A link to the immune system in the radiation response. Cancer Letters 2015;368:275-89. [DOI: 10.1016/j.canlet.2015.02.019] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 11.5] [Reference Citation Analysis]
312 Lauber K, Brix N, Ernst A, Hennel R, Krombach J, Anders H, Belka C. Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity. Cancer Letters 2015;368:209-29. [DOI: 10.1016/j.canlet.2015.02.047] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
313 Burnette B, Weichselbaum RR. The immunology of ablative radiation. Semin Radiat Oncol 2015;25:40-5. [PMID: 25481265 DOI: 10.1016/j.semradonc.2014.07.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
314 Shaverdian N, Veruttipong D, Wang J, Schaue D, Kupelian P, Lee P. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Clin Lung Cancer 2016;17:39-46. [PMID: 26372098 DOI: 10.1016/j.cllc.2015.07.007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
315 Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer Letters 2015;365:23-9. [DOI: 10.1016/j.canlet.2015.05.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
316 Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015;33:7415-22. [PMID: 26148880 DOI: 10.1016/j.vaccine.2015.05.105] [Cited by in Crossref: 114] [Cited by in F6Publishing: 119] [Article Influence: 14.3] [Reference Citation Analysis]
317 Schaue D, Mcbride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 2015;12:527-40. [DOI: 10.1038/nrclinonc.2015.120] [Cited by in Crossref: 251] [Cited by in F6Publishing: 277] [Article Influence: 31.4] [Reference Citation Analysis]
318 De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology 2015;4:e1042198. [PMID: 26464810 DOI: 10.1080/2162402X.2015.1042198] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
319 Gorchs L, Hellevik T, Bruun JA, Camilio KA, Al-Saad S, Stuge TB, Martinez-Zubiaurre I. Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Front Oncol 2015;5:87. [PMID: 26029659 DOI: 10.3389/fonc.2015.00087] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
320 Buchwald ZS, Efstathiou JA. Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer? Bladder Cancer 2015;1:15-27. [PMID: 30561443 DOI: 10.3233/BLC-150014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
321 Butterfield LH. Cancer vaccines. BMJ 2015;350:h988. [PMID: 25904595 DOI: 10.1136/bmj.h988] [Cited by in Crossref: 157] [Cited by in F6Publishing: 166] [Article Influence: 19.6] [Reference Citation Analysis]
322 Zsiros E, Tanyi J, Balint K, Kandalaft LE. Immunotherapy for ovarian cancer: recent advances and perspectives. Curr Opin Oncol 2014;26:492-500. [PMID: 25036883 DOI: 10.1097/CCO.0000000000000111] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
323 Ratikan JA, Micewicz ED, Xie MW, Schaue D. Radiation takes its Toll. Cancer Lett 2015;368:238-45. [PMID: 25819030 DOI: 10.1016/j.canlet.2015.03.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
324 Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: Optimal dose and fractionation. Cancer Lett 2015;368:185-90. [PMID: 25799953 DOI: 10.1016/j.canlet.2015.03.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
325 Persa E, Balogh A, Sáfrány G, Lumniczky K. The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett 2015;368:252-61. [PMID: 25754816 DOI: 10.1016/j.canlet.2015.03.003] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 7.6] [Reference Citation Analysis]
326 Mokhles S, Verstegen N, Maat AP, Birim Ö, Bogers AJ, Mokhles MM, Lagerwaard FJ, Senan S, Takkenberg JJ. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: Results from propensity score analysis. Lung Cancer 2015;87:283-9. [DOI: 10.1016/j.lungcan.2015.01.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
327 Soukup K, Wang X. Radiation meets immunotherapy - a perfect match in the era of combination therapy? Int J Radiat Biol 2015;91:299-305. [PMID: 25630486 DOI: 10.3109/09553002.2014.995383] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
328 Kim MH, Jung SY, Ahn J, Hwang SG, Woo HJ, An S, Nam SY, Lim DS, Song JY. Quantitative proteomic analysis of single or fractionated radiation-induced proteins in human breast cancer MDA-MB-231 cells. Cell Biosci 2015;5:2. [PMID: 26056562 DOI: 10.1186/2045-3701-5-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
329 Finkelstein SE, Salenius S, Mantz CA, Shore ND, Fernandez EB, Shulman J, Myslicki FA, Agassi AM, Rotterman Y, Devries T, Sims R. Combining Immunotherapy and Radiation for Prostate Cancer. Clinical Genitourinary Cancer 2015;13:1-9. [DOI: 10.1016/j.clgc.2014.09.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
330 Kothari G, Foroudi F, Gill S, Corcoran NM, Siva S. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 2015;54:148-57. [PMID: 25140860 DOI: 10.3109/0284186X.2014.939298] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 7.5] [Reference Citation Analysis]
331 Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM. Building immunity to cancer with radiation therapy. Cancer Lett 2015;368:198-208. [PMID: 25592036 DOI: 10.1016/j.canlet.2015.01.009] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
332 Adkins I, Fucikova J, Garg AD, Agostinis P, Špíšek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 2014;3:e968434. [PMID: 25964865 DOI: 10.4161/21624011.2014.968434] [Cited by in Crossref: 118] [Cited by in F6Publishing: 126] [Article Influence: 14.8] [Reference Citation Analysis]
333 Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015;3:345-355. [PMID: 25527358 DOI: 10.1158/2326-6066.cir-14-0196] [Cited by in Crossref: 407] [Cited by in F6Publishing: 434] [Article Influence: 45.2] [Reference Citation Analysis]
334 Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014;4:325. [PMID: 25506582 DOI: 10.3389/fonc.2014.00325] [Cited by in Crossref: 157] [Cited by in F6Publishing: 173] [Article Influence: 17.4] [Reference Citation Analysis]
335 Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014;14:748. [PMID: 25288198 DOI: 10.1186/1471-2407-14-748] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 8.6] [Reference Citation Analysis]
336 Hiniker SM, Knox SJ. Immunotherapy and radiation. Semin Oncol 2014;41:702-13. [PMID: 25499631 DOI: 10.1053/j.seminoncol.2014.09.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
337 Wu CT, Hsieh CC, Yen TC, Chen WC, Chen MF. TGF-β1 mediates the radiation response of prostate cancer. J Mol Med (Berl) 2015;93:73-82. [PMID: 25228112 DOI: 10.1007/s00109-014-1206-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
338 Aryankalayil MJ, Makinde AY, Gameiro SR, Hodge JW, Rivera-Solis PP, Palayoor ST, Ahmed MM, Coleman CN. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res 2014;182:139-48. [PMID: 25003313 DOI: 10.1667/RR13731.1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
339 Dagan R, Amdur RJ. Optimal fractionation for SBRT for spinal metastasis. Stereotactic Body Radiation Therapy: Spinal Metastasis 2014. [DOI: 10.2217/ebo.13.690] [Reference Citation Analysis]
340 Palmer JD, Zaorsky NG, Witek M, Lu B. Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis 2014;6:387-98. [PMID: 24688783 DOI: 10.3978/j.issn.2072-1439.2013.12.04] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
341 Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res 2014;182:126-38. [PMID: 24960415 DOI: 10.1667/RR13374.1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
342 Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys 2014;88:1188-95. [PMID: 24661671 DOI: 10.1016/j.ijrobp.2013.12.043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
343 Palayoor ST, John-Aryankalayil M, Makinde AY, Falduto MT, Magnuson SR, Coleman CN. Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation. Mol Cancer Res 2014;12:1002-15. [PMID: 24784841 DOI: 10.1158/1541-7786.MCR-13-0623] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
344 Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 2014;29:153-61. [PMID: 24693958 DOI: 10.1089/cbr.2013.1578] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
345 de la Cruz-Merino L, Illescas-Vacas A, Grueso-López A, Barco-Sánchez A, Míguez-Sánchez C. Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. Front Immunol. 2014;5:102. [PMID: 24672524 DOI: 10.3389/fimmu.2014.00102/abstract] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
346 de la Cruz-Merino L, Illescas-Vacas A, Grueso-López A, Barco-Sánchez A, Míguez-Sánchez C; Cancer Immunotherapies Spanish Group (GETICA). Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. Front Immunol 2014;5:102. [PMID: 24672524 DOI: 10.3389/fimmu.2014.00102] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
347 Hellevik T, Martinez-Zubiaurre I. Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol 2014;4:1. [PMID: 24478982 DOI: 10.3389/fonc.2014.00001] [Cited by in Crossref: 82] [Cited by in F6Publishing: 91] [Article Influence: 9.1] [Reference Citation Analysis]
348 Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci 2014;15:927-43. [PMID: 24434638 DOI: 10.3390/ijms15010927] [Cited by in Crossref: 156] [Cited by in F6Publishing: 173] [Article Influence: 17.3] [Reference Citation Analysis]
349 Thompson RF, Maity A. Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. Adv Exp Med Biol 2014;772:147-65. [PMID: 24272358 DOI: 10.1007/978-1-4614-5915-6_7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
350 Ratikan JA, Sayre JW, Schaue D. Chloroquine engages the immune system to eradicate irradiated breast tumors in mice. Int J Radiat Oncol Biol Phys 2013;87:761-8. [PMID: 24138918 DOI: 10.1016/j.ijrobp.2013.07.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
351 Dudek AM, Martin S, Garg AD, Agostinis P. Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol. 2013;4:438. [PMID: 24376443 DOI: 10.3389/fimmu.2013.00438] [Cited by in Crossref: 223] [Cited by in F6Publishing: 237] [Article Influence: 22.3] [Reference Citation Analysis]
352 Zeng J, Harris TJ, Lim M, Drake CG, Tran PT. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int 2013;2013:658126. [PMID: 24324970 DOI: 10.1155/2013/658126] [Cited by in Crossref: 41] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
353 Frey B, Rubner Y, Kulzer L, Werthmöller N, Weiss EM, Fietkau R, Gaipl US. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 2014;63:29-36. [PMID: 24052136 DOI: 10.1007/s00262-013-1474-y] [Cited by in Crossref: 100] [Cited by in F6Publishing: 105] [Article Influence: 10.0] [Reference Citation Analysis]
354 Lumniczky K, Sáfrány G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett 2015;356:114-25. [PMID: 23994343 DOI: 10.1016/j.canlet.2013.08.024] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
355 Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine & Growth Factor Reviews 2013;24:319-33. [DOI: 10.1016/j.cytogfr.2013.01.005] [Cited by in Crossref: 155] [Cited by in F6Publishing: 162] [Article Influence: 15.5] [Reference Citation Analysis]
356 Good JS, Harrington KJ. The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. Clin Oncol (R Coll Radiol) 2013;25:569-77. [PMID: 23850153 DOI: 10.1016/j.clon.2013.06.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
357 Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756-2763. [PMID: 23863633 DOI: 10.1172/jci69219] [Cited by in Crossref: 181] [Cited by in F6Publishing: 200] [Article Influence: 18.1] [Reference Citation Analysis]
358 Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, Mollema R, van Tets WF, Warner A, Joosten JJ. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24:1543-1548. [PMID: 23425947 DOI: 10.1093/annonc/mdt026] [Cited by in Crossref: 177] [Cited by in F6Publishing: 218] [Article Influence: 17.7] [Reference Citation Analysis]
359 Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256-265. [PMID: 23291374 DOI: 10.1093/jnci/djs629] [Cited by in Crossref: 660] [Cited by in F6Publishing: 716] [Article Influence: 66.0] [Reference Citation Analysis]
360 Schaue D, Kachikwu EL, McBride WH. Cytokines in radiobiological responses: a review. Radiat Res 2012;178:505-23. [PMID: 23106210 DOI: 10.1667/RR3031.1] [Cited by in Crossref: 233] [Cited by in F6Publishing: 243] [Article Influence: 21.2] [Reference Citation Analysis]
361 Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012;2:153. [PMID: 23112958 DOI: 10.3389/fonc.2012.00153] [Cited by in Crossref: 162] [Cited by in F6Publishing: 208] [Article Influence: 14.7] [Reference Citation Analysis]
362 Burnette B, Fu YX, Weichselbaum RR. The confluence of radiotherapy and immunotherapy. Front Oncol 2012;2:143. [PMID: 23087904 DOI: 10.3389/fonc.2012.00143] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
363 Weiss EM, Wunderlich R, Ebel N, Rubner Y, Schlücker E, Meyer-Pittroff R, Ott OJ, Fietkau R, Gaipl US, Frey B. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol 2012;2:132. [PMID: 23087898 DOI: 10.3389/fonc.2012.00132] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
364 Kwilas AR, Donahue RN, Bernstein MB, Hodge JW. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2012;2:104. [PMID: 22973551 DOI: 10.3389/fonc.2012.00104] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
365 Schaue D, Xie MW, Ratikan JA, McBride WH. Regulatory T cells in radiotherapeutic responses. Front Oncol 2012;2:90. [PMID: 22912933 DOI: 10.3389/fonc.2012.00090] [Cited by in Crossref: 43] [Cited by in F6Publishing: 60] [Article Influence: 3.9] [Reference Citation Analysis]
366 Mcbride WH, Schaue D. In situ Tumor Ablation with Radiation Therapy: Its Effect on the Tumor Microenvironment and Anti-tumor Immunity. In: Keisari Y, editor. Tumor Ablation. Dordrecht: Springer Netherlands; 2013. pp. 109-19. [DOI: 10.1007/978-94-007-4694-7_6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
367 Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol. 2012;189:558-566. [PMID: 22685313 DOI: 10.4049/jimmunol.1200563] [Cited by in Crossref: 257] [Cited by in F6Publishing: 276] [Article Influence: 23.4] [Reference Citation Analysis]
368 Coventry BJ, Ashdown ML. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res 2012;4:137-49. [PMID: 22740774 DOI: 10.2147/CMAR.S31887] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
369 Jabbour SK, Berman AT, Simone CB 2nd. Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2017;6:113-8. [PMID: 28529894 DOI: 10.21037/tlcr.2017.04.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
370 Campbell AM, Decker RH. Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2017;6:220-9. [PMID: 28529904 DOI: 10.21037/tlcr.2017.03.02] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
371 Flynn JP, O'Hara MH, Gandhi SJ. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). Transl Lung Cancer Res 2017;6:159-68. [PMID: 28529898 DOI: 10.21037/tlcr.2017.03.07] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
372 Alley EW, Katz SI, Cengel KA, Simone CB 2nd. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res 2017;6:212-9. [PMID: 28529903 DOI: 10.21037/tlcr.2017.04.01] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]